Key clinical point: A genetic test refined the ischemic stroke risk of atrial fibrillation patients with low CHA2DS2-VASc scores.
Major finding: AFib patients with low CHA2DS2-VASc scores but high genetic-test scores had 3.5-fold more ischemic strokes than patients with low genetic scores.
Study details: Post-hoc analysis of 11,164 patients with AFib enrolled in the ENGAGE AF-Timi 48 study.
Disclosures: ENGAGE AF-TIMI48 was sponsored by Daiichi Sankyo, the company that markets edoxaban (Savaysa). Dr. Marston had no disclosures.
Marston NA et al. AHA 2019, Abstract 336.